Mytolac (Lanreotide Acetate)

Lanreotide Acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a long‑acting injectable for subcutaneous use. It reduces excess growth hormone secretion in patients with acromegaly and controls hormone‑producing neuroendocrine tumors. GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mytolac, a long‑acting somatostatin analog, is employed in endocrine disorders that involve excess hormone secretion. Acromegaly: normalises elevated growth hormone levels and reduces associated tumor size. Neuroendocrine tumors: controls hormone production and slows tumor progression. Carcinoid syndrome: alleviates flushing and diarrhoea by inhibiting serotonin release.

Mytolac may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema - Diarrhoea - Nausea or abdominal discomfort - Headache - Hyperglycaemia - Fatigue

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmias - Pituitary apoplexy in patients with adenomas

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood glucose: assess for hyperglycaemia, especially in diabetic patients. - Evaluate gallbladder status: ultrasound if history of gallstones. - Review cardiac function: caution in patients with known arrhythmias. - Adjust concomitant hormone therapies: watch for additive effects. - Use with caution in renal impairment: dose may need modification. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can affect the pharmacokinetics or pharmacodynamics of several agents.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide levels, risking toxicity. - Other somatostatin analogues: additive hormonal suppression. - Insulin: enhanced hypoglycaemic effect.

Moderate Interactions (Monitor Closely): - Oral glucose‑lowering agents: may require dose adjustment. - CYP450 substrates metabolised by hepatic enzymes: potential altered clearance. - Dopamine agonists: possible synergistic effects on hormone suppression.